Novartis prices lung cancer drug at $17,950 for 28-day supply
Novartis AG on Wednesday priced its treatment for a hard-to-treat form of lung cancer at the U.S. wholesale acquisition cost of $17,950 for a 28-day supply, following the drug’s approval by regulators. The drug, Tabrecta, has been approved by the U.S. Food and Drug Administration months ahead of schedule to treat patients with a MET …